• Revenue Growth: Q4 revenue rose to $7.2 million from $3.1 million in the same period last year, with full-year revenue reaching $21.0 million compared to $13.5 million in 2022.

• R&D Investments: R&D expenses increased to $22.4 million in Q4 and $88.2 million for the full year, reflecting clinical trial and personnel costs.

• G&A Expenses: General and administrative expenses slightly increased to $6.2 million in Q4 and $26.4 million for the full year.

• Net Loss: Net loss for Q4 was $19.6 million, with a full-year net loss of $89.2 million, including net interest income.

• Cash Position: Cash, cash equivalents, and marketable securities totaled $192.0 million, funding operations into 2026.

• Share Count: Issued and outstanding shares totaled 47,829,529 as of December 31, 2023.

• Warning! GuruFocus has detected 6 Warning Signs with TCRX.

On March 6, 2024, TScan Therapeutics Inc (NASDAQ:TCRX) released its 8-K filing, announcing its financial results for the fourth quarter and full year ended December 31, 2023, along with a comprehensive business update. The biopharmaceutical company, which specializes in T-cell receptor (TCR) engineered T cell therapies for cancer treatment, reported significant progress in its clinical pipeline and financial growth.

Financial Performance and Clinical Advancements

TScan Therapeutics Inc (NASDAQ:TCRX) highlighted its clinical advancements, including positive data from its Phase 1 study of TSC-100 and TSC-101 for treating hematologic malignancies. The company also announced the clearance of two additional INDs for its Solid Tumor Program, marking a significant step forward in its clinical development.

From a financial perspective, TScan reported a substantial increase in revenue for both the fourth quarter and the full year, primarily due to the timing of research activities related to a collaboration agreement with Amgen. However, the company also saw an increase in research and development expenses, driven by clinical trial costs, personnel expansion, and facilities growth. General and administrative expenses also rose slightly due to legal and professional fees.

Strategic Business Developments

Alongside its financial results, TScan Therapeutics Inc (NASDAQ:TCRX) provided updates on its business developments. The company is actively enrolling patients in its solid tumor clinical trial and anticipates initial data in 2024. TScan also expanded its leadership team with key appointments and promotions, reflecting its commitment to advancing its strategic objectives.